ivermectin - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.48 [0.11, 1.99]< 10%1 study (1/-)84.4 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.48 [0.14, 1.64]< 10%2 studies (2/-)87.7 %some concernnot evaluable moderateimportant-
clinical improvement 1.19 [0.38, 3.72]> 10%1 study (1/-)61.4 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 1.19 [0.38, 3.72]> 10%1 study (1/-)61.4 %some concernnot evaluable moderateimportant-
PCR-negative conversion 0.92 [0.77, 1.09]> 10%1 study (1/-)17.3 %lownot evaluable highimportant-
PCR-negative conversion (7-day) 0.92 [0.77, 1.09]> 10%1 study (1/-)17.3 %lownot evaluable highimportant-
ventilation 0.42 [0.02, 7.39]< 10%1 study (1/-)72.0 %some concernnot evaluable moderateimportant-

safety endpoints 00

serious adverse events 1.00 [0.03, 31.59]< 10%1 study (1/-)50.0 %some concernnot evaluable moderateimportant-
adverse events 1.30 [0.47, 3.57]< 10%2 studies (2/-)30.8 %some concernnot evaluable moderatenon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.